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Abstract
Nitric oxide (NO) may play important roles in rheumatoid arthritis
(RA). RA is an inflammatory disease involving joints and other
systems including salivary glands. To assess NO production in
RA patients, we compared levels of serum, urine, and salivary
nitrite and nitrate (NOx) in patients with RA and normal subjects,
and we examined the relationships of these measures to disease
activity. Serum, urine, and NOx levels as well as renal creatinine,
NOx clearance and fractional excretion rates were compared in
25 RA patients and 20 age- and gender-matched healthy
controls. Subjects were hospitalized for 3 days and placed on a
NOxrestricted diet. NOx was assayed using nitrate reductase
and the Griess reagent. RA activity was assessed using
standard clinical and laboratory measures. While consuming a
restricted diet for 3 days to eliminate the effects of oral intake of
NOx, 24 hour urinary NOx excretion decreased in both RA
patients and healthy controls. Urine NOx levels at all time points
were not significantly different between RA patients and normal
subjects. Serum NOx levels also decreased during the 3 days of
NOx restriction, but RA patients had higher serum NOx levels at
all time points compared with the control group. Likewise, serum
NOx/creatinine ratios were higher in RA patients than in
controls. Although basal salivary flow rate and tear flow were
lower in RA patients, salivary NOx levels did not differ between
normal and RA subjects. While renal creatinine clearance was
not different between the two groups, we found that RA patients
had lower renal NOx clearance and lower renal NOx fractional
excretion. After correction of p values for multiple comparisons,
there were no significant relationships for the RA group between
measures of disease activity and the urinary NOx, serum NOx, or
urinary NOx clearance. Despite interest in the use of NO as a
marker of disease activity, alterations in renal NOx clearance and
fractional excretion in RA make it difficult to assess in vivo NO
production even with strict dietary restriction of NOx intake.
Introduction
Nitric oxide (NO) is an important mediator of diverse physio-
logic and pathologic processes, including arthritis [1,2]. Joint
inflammation in autoimmune MRL-lpr/lpr mice and rats with
adjuvant-induced arthritis [3-9] is dependent on the enhanced
production of NO. NO, a lipid- and water-soluble gas, is ideally
suited as a potent inflammatory mediator because of its strong
reactivity with oxygen, superoxide, and iron-containing com-
pounds. This inherent reactivity of NO translates into a rela-
tively short half-life (for example 1 to 10 s), which has made it
technically difficult to quantify in solution. Instead of directly
measuring NO, investigators have estimated NO production
by measuring levels of nitrate (NO3
-) and nitrite (NO2
-), stable
anions derived from the reaction of NO with superoxide. In
general, serum levels and urinary excretion of nitrite + nitrate
(NOx) reflect the total production of NO by the body [10,11].
Care must be taken in the interpretation of results from these
studies, because ingested nitrite or nitrate and renal insuffi-
ciency elevate both serum and urine nitrate as well as nitrite
[10,12,13].
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Although previous work has provided evidence in rheumatoid
arthritis (RA) for increased production of systemic NO [14-21]
and increased expression of inducible NO synthase (NOS2)
and production of NO [22], most studies of urine and serum
NOx levels have been performed in patients eating a normal
diet [17] or after only an overnight fast [15]. Other approaches
that assess NO production are less subject to dietary influ-
ences. For example, nitrotyrosines, which are formed from the
reaction of peroxynitrite (a product of NO and superoxide) with
tyrosine, can be measured by immunoassay or high-perform-
ance liquid chromatography [16,23]. Using this method, Kaur
and Halliwell [16] have detected nitrotyrosines in serum and
synovial fluid from patients with active RA, but not in serum
from controls.
In the present study, we assessed NO production in vivo by
measuring levels of NOx in urine, serum, and saliva in patients
with active RA and in normal subjects under conditions of
strict dietary NOx restriction. In a comparison between
patients with RA and normal subjects, we found that patients
with RA had comparable levels of NOx in urine and saliva, ele-
vated serum NOx and serum NOx/creatinine, normal renal cre-
atinine clearance, and reduced renal NOx clearance and
fractional excretion. The reduced renal NOx clearance and
fractional excretion limit the use of serum NOx and urine NOx
excretion as parameters of NO production in patients with RA
and their potential as disease markers.
Materials and methods
Patients and controls
Twenty-five patients who met the American College of Rheu-
matology 1987 revised criteria [24] for the classification of RA
were recruited from the Duke University Medical Center
(DUMC) Rheumatology Outpatient Clinics. The patients were
taking stable doses of prednisone (not more than 10 mg/day)
and nonsteroidal anti-inflammatory drugs (NSAIDs) for at least
2 weeks before study entry. If they were taking second-line
drugs, such as methotrexate, hydroxychloroquine, gold, sul-
fasalazine, or azathioprine, doses of these medications were
stable for at least 4 weeks before study entry. No subjects
were taking anti-cytokine agents such as anti-TNF antibody, a
treatment that we have shown decreases the overexpression
of blood mononuclear cell NOS2 in RA [25]. For comparison,
20 age-matched (within 5 years) and gender-matched sub-
jects without RA were recruited by newspaper advertisement.
Patients and controls who had coexisting chronic inflammatory
conditions, active infections, malignancy, cirrhosis, or a serum
creatinine level of more than 2.5 mg/dl were excluded from
participation. Patients were not allowed nitrate-containing
medications or permitted to smoke during the study period.
The DUMC Institutional Review Board approved the protocol,
and informed consent was obtained from each subject before
participation. These are the same patient and control subjects
a s  t h o s e  r e p o r t e d  p r e v i o u s l y  i n  w h o m  w e  s h o w e d  g r e a t e r
NOS2 expression and in vitro NO production in the patients
with RA than in controls [22].
Study design
Eligible subjects were hospitalized for 3 days on the inpatient
unit of the General Clinical Research Center at DUMC. Sub-
jects had a complete history and physical examination at base-
line to confirm eligibility. In addition, the patients with RA were
comprehensively evaluated for disease activity with the use of
the following measures:
1. Tender and swollen joint count (maximum of 68 tender and
66 swollen joints).
2. Duration of morning stiffness.
3. Patient assessment of pain on a 10 cm visual analog scale.
4. Physician global assessment of disease activity with the use
of a 10 cm analog scale.
5. Functional capacity determined with the modified Stanford
Health Assessment Questionnaire (mHAQ) [26].
The functional class was determined with the American Col-
lege of Rheumatology 1991 revised criteria for the classifica-
tion of global functional status [27]. Rheumatologic
assessments and routine laboratory studies were performed at
baseline and on day 3. Because no significant differences in
disease measures were found between baseline and day 3,
the disease-related parameters at baseline were used in the
analysis below.
The characteristics of the patients with RA and the healthy
controls have been published previously [22]. The two groups
were similar with respect to median age (patients with RA, 58
years; controls, 56 years) and gender (patients with RA, 17
women and 8 men; controls, 14 women and 6 men). The
median duration of disease for the patients with RA was 9
years. In general, the patients with RA had severe disease, as
reflected by the high proportion of patients with subcutaneous
nodules (48%), the high proportion of patients currently taking
a second-line drug (72%), and the frequent past use of sec-
ond-line drugs (72%). Disease activity in the RA group was
characterized by high median tender (31) and swollen (28)
joint counts, prolonged morning stiffness (median duration 60
minutes), a median erythrocyte sedimentation rate of 26 mm/
hour, a median CRP of 13 mg/l, and moderate functional dis-
ability (median mHAQ score 1.62). No control subjects were
taking prednisone, and only two controls were taking a NSAID
at the time of the study.
Dietary intervention
The subjects were fed a low-NOx diet that met the recom-
mended allowances for weight maintenance in kilocalories,Available online http://arthritis-research.com/content/8/5/R140
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carbohydrate, fat, and protein. Two caloric diets were available
for selection by subjects: first, a 2,000 kcal diet of 18% pro-
tein, 60% carbohydrates, and 22% fat, yielding about 100
µmoles of NOx per day; and second, a 2,500 kcal diet of 19%
protein, 60% carbohydrates, and 21% fat, yielding about 110
µmoles of NOx per day. The amount of NOx in these diets was
determined as described previously [28]. The diet allowed
unlimited consumption of distilled water. A research dietician
obtained a dietary history from each subject at the time of
admission to estimate the oral intake of NOx during the previ-
ous 24 hours and also monitored the daily oral intake of food
and beverages in the hospital to estimate the daily consump-
tion of NOx.
Blood, urine, and saliva collection, and NOx assays
Blood samples were drawn by venipuncture from subjects at
0, 24, 48, and 72 hours for determination of serum creatinine
and NOx concentrations. NO reacts with oxygen to form nitrite
and nitrate. We used the Griess reagent to measure nitrite
[29,30]. We first converted all nitrate to nitrite with bacterial
nitrate reductase, and then this nitrite (representing total nitrite
plus nitrate [NOx]) was measured with the Griess reagent.
Propan-2-ol ('isopropanol') was added to urine collected dur-
ing a 24 hour period at a ratio of 1:10 (propan-2-ol/urine) to
prevent bacterial growth, because contaminating bacterial
enzymes can introduce errors. Urine and saliva were used
unprocessed, but serum samples were filtered with Centricon
filters (Amicon, Beverly, MA, USA) before performing the NOx
assays. We incubated 50 µl of sample for 30 minutes with 7
µl of 1 M Tris pH 7.5, 10 µl of 0.02 mM NADPH, 20 µl of 5
mM glucose 6-phosphate (G6P), 3 µl of 10 units/ml glucose-
6-phosphate dehydrogenase (G6PD), and 10 µl of a 10 unit/
mL solution of nitrate reductase at room temperature (20 to
23°C). The G6P and G6PD were used to eliminate excess
NADPH, which might interfere with the overall Griess reaction.
We incubated 75 µl of this mixture for 10 minutes with 75 µl
of Griess reagent I (3% sulfanilamide in 2.5% phosphoric
acid) and Griess reagent II (0.3% naphthylethylenediamine in
2.5% phosphoric acid) at room temperature. The absorbances
at 550 nm were measured, and concentrations of NOx were
determined by comparison with a standard curve generated
with reagent nitrate.
Twenty-four-hour urine samples were collected on day 1 (0 to
24 hours), day 2 (24 to 48 hours), and day 3 (48 to 72 hours)
to quantify urinary excretion of NOx. Urine volume and creati-
nine content were measured for each 24-hour sample to cal-
culate creatinine and NOx clearances. The renal clearance of
NOx was calculated by the following formula: clearance =
(Urine flow rate (liters/24 hours) × Urine NOx (mol/l))/(Serum
NOx (mol/l)). Renal fractional excretion of NOx was deter-
mined by dividing the renal NOx clearance by the creatinine
clearance. Saliva specimens were obtained after 72 hours for
measurement of basal and stimulated salivary NO production
with the use of a method described previously [31]. Subjects
first rinsed their mouth with an antiseptic (Peridex) to reduce
bacterial contamination. For basal measurements, 0.2 to 0.3
ml of saliva was collected within 1 minute of the antiseptic
rinse. For measurement of stimulated flow, subjects rinsed
their mouth with 1 ml of lemon juice followed by a second rinse
with distilled water. Samples (0.2 to 0.3 ml) were collected at
0 to 1 minute and at 5 to 6 minutes. The Schirmer's tear test
was done without anesthesia as noted previously [32].
Analyses
Descriptive statistics were expressed in terms of the median
and interquartile range for continuous variables. Comparisons
between cases and controls regarding various parameters of
NOx, NOS, and disease measures were made using the Wil-
coxon rank sum test. The comparisons of renal clearance and
fractional excretion of NOx between cases and controls in
each of the three 24-hour time periods used only the 23 RA
Table 1
Oral NOx intake before admission and during ingestion of the nitrate- and nitrite-restricted diet
Period Group n Median NOx intake (µmol) 
(interquartile range)
p
Before admission Normal 20 1,875 (94–13,900) NS
RA 25 957 (101–5,162)
Hospital day 1 (0–24 h) Normal 20 111 (98–139)
RA 25 98 (54–150)
Hospital day 2 (24–48 h) Normal 20 126 (98–140)
RA 25 123 (89–140)
Hospital day 3 (48–72 h) Normal 20 126 (112–140)
RA 25 119 (76–140)
NOx, nitrite + nitrate; NS, not significant (comparing normal and RA); RA, rheumatoid arthritis.Arthritis Research & Therapy    Vol 8 No 5    Weinberg et al.
Page 4 of 9
(page number not for citation purposes)
patients and 17 controls for whom assay results were available
for the first two time periods. For the 8 RA patients with miss-
ing observations for the third 24-hour period, it was conserva-
tively assumed that their NOx clearance and fractional
excretion on day 3 were the same as that on day 2 since the
15 other RA patients all had lower values on day 3 for both of
these measures. The relationship of urinary NOx to disease
measures was determined using a Spearman correlation
coefficient.
Results
Dietary intake of NOx
The subjects were hospitalized and placed on a NOx-
restricted diet to minimize exogenous sources of these
constituents. The pre-study dietary content of NOx was highly
variable between individuals (Table 1), but normal subjects
were not significantly different from patients with RA. Once
individuals had been placed on the restricted diet, we con-
firmed by careful history and inspection of food trays that they
had consumed only the minimal amounts of NOx allowed by
the diet. Although control subjects on days 2 and 3 ingested
slightly more NOx than RA subjects did, these differences
were very small in comparison with the measured levels of
these compounds in the serum and urine.
Urine and serum NOx levels
In conditions of low ingestion of exogenous NOx and normal
function, urinary NOx excretion reflects total production of NO
by the body [10,33]. On the basis of other studies [10,12,33],
we predicted that our dietary intervention would quickly
decrease urinary NOx excretion, which would then stabilize
after about 24 to 48 hours. This prediction was confirmed in
healthy controls and patients with RA, whose urinary NOx
excretions decreased by 21 to 30% over the 72-hour interval
(Figure 1). The differences at each period of urine collection
were not different when comparing normal controls with
patients with RA (p > 0.05). Serum NOx levels decreased to
an even greater degree with dietary NOx restriction (as much
as 42% decrease) and stabilized over 72 hours (Figure 2).
Despite an absence of increased urinary NOx excretion in
patients with RA, patients with RA had significantly higher
serum NOx levels at all time points (Figure 2). Likewise, day 3
serum NOx/creatinine ratios were significantly higher in
patients with RA than in controls, whereas urinary NOx/creat-
inine ratios were not significantly different between these two
groups (Figure 3). The use of NOx/creatinine ratios acts as a
control for individual differences in creatinine clearances. The
finding of increased NOx and NOx/creatinine ratios in serum
(but not in urine) in patients with RA raised the possibility that
controls and subjects with RA might differ in their renal elimi-
nation of NOx.
Renal clearance and fractional excretion of NOx
The creatinine clearance was slightly higher in patients with
RA, but this difference was not statistically significant (Table
2). This finding indicates that a reduction in glomerular filtra-
tion rate in patients with RA was not a likely explanation for any
elevated serum and urine NOx levels in RA. However, the renal
clearance and fractional excretion of NOx were significantly
lower in subjects with RA than in controls at all time points.
Figure 1
Urinary excretion of NOx Urinary excretion of NOx. Consecutive 24-hour urine samples were col-
lected from 25 patients with active rheumatoid arthritis (RA) and 20 
healthy controls (N) who were receiving a diet low in nitrate and nitrite. 
During each of the time periods, no statistically significant differences 
were observed between the two groups in 24-hour urinary excretion of 
NOx. Values are expressed as medians (horizontal lines), means (filled 
circles), interquartile ranges (boxes), and 10th to 90th centile ranges 
(whiskers). NOx, NO2
- (nitrite) + NO3
- (nitrate).
Figure 2
Serum concentration of NOx Serum concentration of NOx. Serum was obtained from 25 patients 
with active rheumatoid arthritis (RA) and 20 healthy controls (N) at 0, 
24, 48, and 72 hours after the initiation of a diet low in nitrate and 
nitrite. Serum NOx concentrations were higher in the RA group than in 
the control group at 0, 24, 48, and 72 hours (p = 0.028, 0.0004, 
0.046, and 0.053, respectively). Values are expressed as medians (hor-
izontal lines), means (filled circles), interquartile ranges (boxes), and 
10th to 90th centile ranges (whiskers). NOx, NO2
- (nitrite) + NO3
- 
(nitrate).Available online http://arthritis-research.com/content/8/5/R140
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There was day-to-day variability in the renal clearance of NOx,
with lower clearances at late time points as the NOx-restricted
diet diminished the total NOx load.
We performed a subgroup analysis of the patients with RA to
investigate whether certain medications might be associated
with altered renal clearance of NOx. The median urinary NOx
clearance was higher in NSAID users (n = 13) than in non-
users (n = 12) (49.8 ml/min versus 23.9 ml/min, respectively;
p = 0.017). There were no significant differences in urinary
NOx clearance between prednisone users (n = 16) and non-
users (n = 9) (38.7 ml/min versus 53.1 ml/min, respectively)
and methotrexate users and non-users (33.8 ml/min versus
40.9 ml/min, respectively). Our data indicate that anti-rheu-
matic medications were not likely to be responsible for the
lower renal clearance of NOx in the patients with RA. How-
ever, it is possible that an analysis of larger numbers of sub-
jects might show differences.
Saliva and tears
Saliva can contain large amounts of NO catabolites [13,34].
Dietary nitrate is converted to nitrite in saliva, is swallowed,
and then may appear as nitrate or nitrite in saliva (the entero-
salivary circulation), with salivary NOx sometimes reaching mil-
limolar concentrations [13,34]. Salivary flow is regulated in
part by NO [31]. The prevalence of sicca symptoms in RA
ranges from 25% to 65% [35-39]. We examined basal and
stimulated salivary flow and basal tear flow (Schirmer's tear
test), and we measured NOx levels in saliva (Table 3). Unstim-
ulated and stimulated salivary flow rates were significantly
lower in subjects with RA than in controls. Similarly, Schirmer's
tear test demonstrated that patients with RA had a lower tear
flow than healthy subjects. We did not measure NOx levels in
tears. Basal and stimulated salivary NOx levels were not differ-
ent between normal controls and patients with RA (Table 3).
Relationship of NO parameters to disease activity
In an earlier report of studies involving these subjects, we
showed that the NOS activity of freshly isolated peripheral
blood mononuclear cells (PBMCs) was significantly higher in
subjects with RA and that PBMCs produced more NOx in vitro
in the basal state and after stimulation with IFN-γ [22]. Further-
more, NOS activity correlated significantly with the number of
swollen and tender joints. We had postulated that other
measures of NO production (serum NOx, urine NOx, serum
NOx/creatinine ratios, urine NOx/creatinine ratios) would cor-
relate with certain disease activity measures. We therefore
assessed the relationships of the serum NOx levels at 72
hours, the urine NOx excretion during the period from 48 to 72
hours, the serum and urine NOx/creatinine ratios during the
period from 48 to 72 hours, and NOx urinary clearance and
fractional excretion during the period from 48 to 72 hours, rel-
ative to 10 RA activity parameters (erythrocyte sedimentation
rate, serum C-reactive protein, hemoglobin concentration,
duration of morning stiffness, physician assessment of pain
(visual analog scale), patient pain self-assessment (visual ana-
log scale), patient self-assessment of disease severity (visual
analog scale), number of tender joints, number of swollen
joints, and functional disability (mHAQ)). Results showed a
significant correlation of the serum NOx/creatinine ratio with
the number of painful joints (r = 0.59; p = 0.012), physician
assessment of pain (r = 0.40; p = 0.015), and hemoglobin
concentration (r = 0.36; p = 0.030). The urine NOx/creatinine
ratio was significantly correlated with the mHAQ (r = 0.40; p
= 0.047). After corrections for multiple comparisons, none of
these remained significant. Urine NOx clearance and fractional
excretion did not correlate significantly with any of the param-
eters. We conclude that (despite our carefully limiting the die-
tary intake of nitrates and nitrites) serum and urinary measures
of NO production are of limited usefulness as biomarkers of
disease activity in RA. It is possible that stronger correlations
might be found by analyzing larger numbers of subjects.
Discussion
NO is synthesized from L-arginine by a family of enzymes
known as nitric oxide synthases. These enzymes are encoded
by three separate genes and are NOS1 (neural NOS), NOS2
(inducible NOS), and NOS3 (endothelial NOS). NOS1 and
NOS3 are calcium-dependent and generally produce low lev-
els of NO involved in normal physiologic processes. In con-
trast, NOS type 2 is calcium-independent. Its expression is
upregulated by IFNα, IFNγ, IL-1, and TNF-α as well as other
pro-inflammatory mediators, resulting in sustained and high-
level NO output [40,41].
Several lines of evidence implicate NO in the pathogenesis of
joint inflammation. Rodents in animal models of arthritis gener-
Figure 3
NOx/creatinine ratios in urine and serum NOx/creatinine ratios in urine and serum. Urine and serum samples 
from 25 patients with active rheumatoid arthritis (RA) and 20 healthy 
controls (N) were analyzed 72 hours after initiation of a diet low in 
nitrate and nitrite. NOx/creatinine ratios were calculated and plotted. 
The difference in serum NOx/creatinine values between the RA and 
control groups was statistically significant (p = 0.013). The difference 
between control and RA subjects for urine NOx/creatinine was not sta-
tistically significant. NOx, NO2
- (nitrite) + NO3
- (nitrate).Arthritis Research & Therapy    Vol 8 No 5    Weinberg et al.
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ate abundant quantities of NO, as reflected in high levels of
serum and urinary NOx that develop in association with dis-
ease manifestations [3-6,42]. Treatment of these animals with
NOS inhibitors or NO quenchers suppresses NO production
and effectively abrogates joint inflammation. These findings
have prompted studies in humans to determine whether
patients with RA, like the rodents with arthritis, also have
heightened NO production. Some investigators have analyzed
NO production and NOS in human synovial tissue. For
example, Sakurai and colleagues [43] showed that macro-
phages and endothelial cells from synovial tissue of patients
with RA express NOS2 mRNA and protein, and generate NO
in vitro. We also noted that circulating mononuclear cells from
patients with RA are activated to express NOS type 2 and
overproduce NO [22].
Other approaches have focused on systemic NO production.
In one study, Grabowski and colleagues [15] showed that
patients with RA have threefold higher urinary nitrate/creati-
nine ratios than controls, implying that urinary NOx can be
used in this clinical setting as a reliable index of excessive NO
production. Farrell and colleagues found that patients with RA
or osteoarthritis (OA) had higher serum nitrite (not nitrite +
nitrate) levels than normal controls (with RA being higher than
OA) [17]. Similarly, Euki and colleagues found that serum
nitrite was higher in patients with RA than in normal controls
and patients with OA, and that nitrite levels were correlated
with clinical parameters of RA activity, C-reactive protein,
serum TNF, and serum IL-6 [14]. These workers did not con-
trol NOx intake [14,17]. Onur and colleagues showed that
patients with RA had higher serum NOx levels than controls,
and that NOx was correlated significantly with C-reactive pro-
tein and clinical disease activity [18]. The subjects were told
to avoid foods high in nitrate for 3 days before blood samples
were taken, and were asked to fast overnight before sampling
blood [18]. Pham and colleagues showed that patients with
RA had significantly higher serum NOx levels than normal con-
trol individuals and patients with OA [19].
The investigations of Onur and colleagues and Pham and col-
leagues did not correct for renal function. Choi noted higher
serum NOx levels in patients with RA than in healthy individu-
als, but he found no correlation of serum NOx with disease
activity measures [20]. In his studies, subjects were fasted for
only 12 hours, and there was no correction for renal function.
Ersoy and colleagues noted that patients with RA had higher
serum NOx levels than normal controls, and that NOx levels
were significantly correlated with disease activity [21]. These
investigators did not control NOx intake or correct for renal
function. Studies with stable isotopic (non-radioactive) L-
arginine can be useful in the evaluation of NO formation in vivo
in humans [44]. However, renal function abnormalities can
result in difficulties in the interpreting results, because serum
and urine nitrate and nitrite containing the isotope label are the
measured products.
Our study of patients with RA with normal renal creatinine
clearance illustrates that serum NOx and urine NOx excretion
levels may be difficult to use as measures of whole-body NO
production, even when one carefully controls NOx ingestion.
We found under conditions of stringent dietary control that uri-
nary NOx levels are no higher in patients with RA than in con-
trols. NO in the presence of superoxide can produce
peroxynitrite, which in turn can nitrate the phenolic group of
Table 2
Renal clearance of creatinine and NOx, and fractional excretion of NOx
Measure Group n Median (interquartile range) p
Creatinine clearance (ml/min) Normal 20 84 (74–97) NS (0.071)
RA 25 99 (82–133)
NOx clearance (ml/min), 0–24 h Normal 17 125(72–209) 0.004
RA 23 31 (16–73)
NOx clearance (ml/min), 24–48 h Normal 17 69 (38–106) 0.026
RA 23 38 (20–58)
NOx clearance (ml/min), 48–72 h Normal 17 47 (20–80) 0.014
RA 23 27 (11–34)
NOx fractional excretion, 0–24 h Normal 17 1.40 (0.78–2.26) 0.004
RA 23 0.35 (0.19–0.82)
NOx fractional excretion, 24–48 h Normal 17 0.81 (0.48–1.23) 0.010
RA) 23 0.29 (0.17–0.71)
NOx fractional excretion, 48–72 h Normal 17 0.56 (0.16–0.94) 0.010
RA 23 0.28 (0.11–0.38)
NOx, nitrite + nitrate; NS, not significant (comparing normal and RA); RA, rheumatoid arthritis.Available online http://arthritis-research.com/content/8/5/R140
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amino acids (especially tyrosine) [23]. Nitrotyrosines were not
assessed in the present study, but others have previously
detected nitrotyrosine in serum of patients with active RA [16].
Although NO incorporated into nitrotyrosines may represent a
source of unmeasured NO catabolite, it is unlikely to be more
than 10% of the total NO formed in the body [45].
Urinary NOx has been generally accepted as a measure of
total body NO production [10,12,46-49]. The proportion of
NOx excreted in the urine constitutes 50 to 60% of the total
body clearance of these compounds, with the remaining
amounts being eliminated in unknown proportions by the exo-
crine glands and by the respiratory and gastrointestinal tracts
[11,12]. The total amount of NOx measured in the urine and
serum derives from both endogenous and exogenous sources.
As shown in our study, individuals vary substantially in their
dietary intake of nitrate and nitrite. Unless individual variability
of NOx intake is taken into account, measures of NOx in urine
and serum will probably not reflect endogenous NO produc-
tion, and exogenous NOx might obscure true differences in
endogenous NOx production. Grabowski and colleagues [15]
found in healthy volunteers that urinary NOx levels after an
overnight fast are not significantly altered by dietary intake of
nitrate and nitrite. Our results demonstrate a significant
decrease in NOx in urine and serum after 24 hours of a NOx-
restricted diet. However, we do not demonstrate a significant
difference in NOx in urine between normal subjects and
patients with RA. This finding suggests that the patients with
RA may have differed from control subjects in the renal elimi-
nation of NOx. Grabowski and colleagues [15] noted a higher
average urinary nitrate/creatinine ratio in patients with RA than
in controls after only an overnight fast. Our analyses showed
that urinary NOx and NOx/creatinine levels after 1, 2, or 3 days
of a NOx-restricted diet were not different between normal and
RA subjects, but serum NOx/creatinine levels were signifi-
cantly higher in our study in patients with RA. However, this
difference is difficult to interpret in view of the finding that
patients with RA have a decrease in renal NOx clearance.
Nitrite and nitrate are each filtered by the kidney and reab-
sorbed in the proximal tubule, but there may be other sites of
tubular reabsorption and secretion [50]. Altered renal NOx
clearance has not previously been described in humans
except in cases with substantial reductions of glomerular filtra-
tion [51]. In the present study, the RA and control groups had
similar creatinine clearances, and none of the subjects had a
serum creatinine above 2 mg/dl. Thus, differences in glomeru-
lar filtration do not seem to explain the lower NOx clearances
in the RA group. Moreover, treatment with NSAIDs, pred-
nisone, or methotrexate was not associated with a lower NOx
clearance, pointing away from concomitant anti-rheumatic
therapy as the cause of the reduced NOx clearance. This anal-
ysis must be interpreted with caution in view of the small num-
bers of subjects in each of the medication subgroups and the
fact that many of the patients were taking multiple anti-rheu-
matic agents. We suspect that the altered renal clearances
and fractional excretions of NOx in patients with RA are due to
intrinsic renal tubular abnormalities. Renal tubular abnormali-
ties have been described in patients with RA and in those with
Sjögren's syndrome [52,53].
Exocrine dysfunction of the lacrimal and salivary glands may
occur in RA, leading in some cases to secondary Sjögren's
syndrome [35-39]. Thus, alterations in NOx excretion (and
possibly NOx clearance comparable to those we note in the
kidney) by the salivary glands might influence NOx levels in
serum and urine. Our studies document low basal salivary flow
and tear flow in patients with RA, but salivary NOx levels after
Table 3
Saliva and lacrimal measures
Measure Group n Median (interquartile range) pa
Unstimulated salivary flow (ml/min) Normal 20 5.5 (4.0–9.5) 0.0009
RA 25 3.0 (1.0–5.0)
Stimulated salivary flow, 15 min (ml/min) Normal 20 8.0 (3.8–10.5) 0.0005
RA 25 4.0 (1.5–4.5)
Basal salivary NOx (µM)b Normal 20 46.1 (19.5–71.3) NS
RA 25 48.8 (31.3–83.4)
Stimulated salivary NOx, 15 min (µM)b Normal 20 48.1 (26.6–98.7) NS
RA 25 37.0 (15.7–81.9)
Schirmer's tear test, left (mm) Normal 19 14.0 (5.0–30.0) 0.025
RA 25 8.0 (2.0–17.5)
Schirmer's tear test, right (mm) Normal 19 12.0 (5.0–30.0) 0.008
RA 25 5.0 (1.5–10.0)
NOx, nitrite + nitrate; aNS*, not significant; RA, rheumatoid arthritis. aComparing normal and RA; bsaliva collected on the third day of the diet.Arthritis Research & Therapy    Vol 8 No 5    Weinberg et al.
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3 days of a low NOx diet were comparable in controls and in
subjects with RA. Although salivary flow can be influenced by
NO [31], we find no evidence that this is disordered in RA. We
did not measure NOx clearance by the salivary glands. We
speculate that salivary gland epithelium, like renal tubular cell
function, which we showed here has an altered NOx clearance
in RA, may also have diminished NOx clearance. This could
modify the excretion of NOx into saliva and partly contribute to
the elevated serum NOx in RA.
Our earlier report of studies of these subjects showed that
NOS activity of freshly isolated PBMCs was significantly
higher in subjects with RA and that isolated PBMCs produced
more NOx in vitro in the basal state and after stimulation with
IFN-γ. In addition, NOS activity was significantly correlated
with the number of swollen and tender joints [22]. Although
NOx is much easier to measure than NOS activity, our results
emphasize the limitations of using serum and urine NOx levels
as indices of NOS activity and NO production in patients with
RA. We have shown how dietary influences and altered urinary
NOx clearances make it difficult to interpret serum and urine
NOx levels. Future studies of NO production in RA are there-
fore likely to be more informative if they focus on specific ana-
tomic or cellular compartments relevant to the
pathophysiology of disease.
Conclusion
Subjects with RA may have altered renal clearance and frac-
tional excretion of NOx. This complicates the interpretation of
measures of serum NOx concentrations and urine NOx levels,
even when one carefully controls NOx ingestion. NOx meas-
ures as parameters of RA activity must be used with caution.
Studies of NO production in RA are likely to be more informa-
tive if they focus on specific anatomic or cellular compart-
ments relevant to the pathophysiology of disease.
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